<DOC>
	<DOCNO>NCT01026467</DOCNO>
	<brief_summary>This phase II trial study well frailty index geriatric assessment work predict toxicity front-line chemotherapy treat patient stage IV non-small cell lung cancer . A frailty index geriatric assessment prior treatment may help identify good treatment regimen</brief_summary>
	<brief_title>Frailty Index Geriatric Assessment Predicting Toxicity Front-Line Chemotherapy Treating Patients With Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine correlation data frailty index geriatric assessment tool level toxicity encounter first two cycle therapy . OUTLINE : Patients complete frailty index geriatric assessment prior begin chemotherapy . Patients receive standard-of-care chemotherapy comprise carboplatin intravenously ( IV ) paclitaxel IV day 1 . Treatment repeat every 21 day 2 course .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Pathological documentation nonsmall cell lung cancer Stage IV disease Prior adjuvant chemotherapy earlier stage nonsmall cell lung cancer allow Patients brain metastasis allow protocol receive brain irradiation neurologically stable Patients malignancy allow protocol unless receive active treatment ( surgery , radiation , chemotherapy immunotherapy ) malignancy Ability understand willingness sign write informed consent document Prior palliative chemotherapy Pregnant and/or lactate woman Prior radiation therapy brain irradiation brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>